| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/01/2006 | EP1620060A2 Methods and devices for the sustained release of multiple drugs |
| 02/01/2006 | EP1620058A2 Composition for improving cognition and memory |
| 02/01/2006 | EP1619947A2 Antibacterial methods and compositions |
| 02/01/2006 | EP1430144A4 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 02/01/2006 | EP1370548B1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 02/01/2006 | EP1343492B1 Treatment of mucositis |
| 02/01/2006 | EP1328266B1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 02/01/2006 | EP1268502B1 O-aryl glucoside sglt2 inhibitors and method |
| 02/01/2006 | EP1267827B1 Use of an aqueous solution for the treatment of try eye |
| 02/01/2006 | EP1194409B1 Pyrazolidinol compounds |
| 02/01/2006 | EP1146894B1 Uses of thank protein, a tnf homologue, to inhibit growth of tumour cells |
| 02/01/2006 | EP1133315B1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 02/01/2006 | EP1104289B1 New oral formulation for 5-ht4 agonists or antagonists |
| 02/01/2006 | EP1001804B1 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| 02/01/2006 | EP0994709A4 Calcium blockers to treat proliferative vitreoretinopathy |
| 02/01/2006 | EP0956040B1 Stimulation of host defense mechanisms against viral challenges |
| 02/01/2006 | EP0898478B1 Stimulation of host defence mechanisms against tumors |
| 02/01/2006 | CN1729192A Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| 02/01/2006 | CN1729017A A preparation and method for weight reduction |
| 02/01/2006 | CN1729012A Method and composition for preventing and treating solid tumors |
| 02/01/2006 | CN1729003A Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 02/01/2006 | CN1729002A Exemestane as chemopreventing agent |
| 02/01/2006 | CN1728995A Dosage forms comprising a cetp inhibitor and an HMG-CoA reductase inhibitor |
| 02/01/2006 | CN1728991A Combination therapy for the treatment of cancer |
| 02/01/2006 | CN1728990A Uses of adenosine A2A receptor antagonists |
| 02/01/2006 | CN1240259C Method for forming holes, using flexible connection board formed thereof and its producing method |
| 02/01/2006 | CN1239485C Benzophenones as inhibitors of IL-1 beta and TNF-alpha |
| 02/01/2006 | CN1239482C Positive modulators for nicotinic receptor agonists |
| 02/01/2006 | CN1239472C HIV integrase inhibitors |
| 02/01/2006 | CN1239212C Device for percutaneous transdermal delivery having coated micro-protrusions |
| 02/01/2006 | CN1239203C Hydrogel composition for transdermal drug delivery |
| 02/01/2006 | CN1239154C 5-HT IA receptor subtype agonist |
| 01/31/2006 | US6992218 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 01/31/2006 | US6992174 Reducing the immunogenicity of fusion proteins |
| 01/31/2006 | US6992097 such as methyl-1-{2-[4-((2R)-2-{2-[(tert-butoxy)carbonylamino]-2-methylpropanoylamino}-3-indol-3-ylpropanoylamino)imidazolyl]-2-phenylacetyl}pyrrolidine-2-carboxylate |
| 01/31/2006 | US6992086 Antagonists of MCP-1 function and methods of use thereof |
| 01/31/2006 | US6992072 comprises pyrimidine-based nucleosides; highly active anti-retroviral therapy; treating lipoatrophy, dyslipidemia, and insulin resistance resulting from administration of nucleoside reverse transcriptase inhibitors |
| 01/31/2006 | US6992071 Methods for modulating phototoxicity |
| 01/31/2006 | US6992067 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 01/31/2006 | US6992060 Short term treatment with composition having gastrin/cholecystokinin receptor ligand and EGF receptor ligand, resulting in prolonged period of increased insulin release |
| 01/31/2006 | US6991928 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 01/31/2006 | US6991920 Peptide for use in human therapeutics and diagnostics |
| 01/31/2006 | US6991916 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 01/31/2006 | US6991817 Acid-modified arabinogalactan protein composition |
| 01/31/2006 | US6991807 Four different dosage forms, two antibiotics inhibiting protein and non-protein synthesis, one comprising immediate release and sustained release, the other three has sustained release forms, twenty-four hour period; bacterial infections |
| 01/31/2006 | US6991785 Administering by tissue absorption |
| 01/26/2006 | WO2006009805A2 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| 01/26/2006 | WO2006009546A2 Method for the production of bio-active substances from the novel actinomycete taxa mar3a and mar3b belonging to the family streptomycetaceae |
| 01/26/2006 | WO2006009465A2 Composition comprising protein material and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009464A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009309A1 Galectin 9-binding protein factor |
| 01/26/2006 | WO2006009092A1 Method of effectively using medicine and method concerning prevention of side effect |
| 01/26/2006 | WO2006008556A1 Imidazole and thiazole derivatives as antiviral agents |
| 01/26/2006 | WO2006008270A1 Use of compounds containing thiol groups as an efflux pump inhibitor |
| 01/26/2006 | WO2006008213A1 Medicaments for inhalation comprising pde iv inhibitors and enantiomercally pure glycopyrrolate salts |
| 01/26/2006 | WO2006007818A2 Method for systemic bio-correction of an organism |
| 01/26/2006 | WO2006007671A2 Therapeutically combinations |
| 01/26/2006 | WO2005120539A3 Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| 01/26/2006 | WO2005107809A3 Antimycobacterial pharmaceutical composition comprising an antitubercular drug |
| 01/26/2006 | WO2005097119A3 Pten inhibitors |
| 01/26/2006 | WO2005094384A3 Methods and compositions for treatment of ion imbalances |
| 01/26/2006 | WO2005063297A3 Melatonin combination therapy for improving sleep quality |
| 01/26/2006 | WO2005048927A3 Methods and reagents for the treatment of inflammatory disorders |
| 01/26/2006 | WO2005027855A3 Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors |
| 01/26/2006 | WO2004113502A3 Identification of therapeutic agents using genetic fingerprinting |
| 01/26/2006 | WO2004014319A3 Screening strategy for anticancer drugs |
| 01/26/2006 | US20060020042 Memantine for the treatment of mild and mild to moderate Alzheimer's disease |
| 01/26/2006 | US20060020024 TNP-470 species, polymer conjugates and use thereof |
| 01/26/2006 | US20060020020 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 01/26/2006 | US20060020008 Compounds, compositions and methods |
| 01/26/2006 | US20060020002 (3a alpha ,4 alpha ,7 alpha ,7a alpha )-Octahydro-3-hydroxy-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (2); steroid mimic; competitive inhibitors of intercellular ligand binding reactions involving CAMs and Leukointegrins; anticarcinogenic agent; autoimmune diseases |
| 01/26/2006 | US20060019988 Compounds, compositions, and methods |
| 01/26/2006 | US20060019970 Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
| 01/26/2006 | US20060019945 Granzyme b inhibitors |
| 01/26/2006 | US20060019930 Treatment and prevention of tissue damage |
| 01/26/2006 | US20060019925 Peritoneal dialysis method |
| 01/26/2006 | US20060019904 Composition for promoting lacrimal secretion |
| 01/26/2006 | US20060019900 Alpha-4 beta-1 integrin ligands for imaging and therapy |
| 01/26/2006 | US20060019888 such as viral myocarditis (Coxsackie virus, echovirus, polio virus) or dilated (congestive) cardiomyopathy, by binding ErbB2-ErbB4 receptors; atpase inhibitors |
| 01/26/2006 | US20060019887 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 01/26/2006 | US20060019883 Use of cyclin D1 inhibitors |
| 01/26/2006 | US20060019876 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 01/26/2006 | US20060019344 C-erbB-2 external domain: gp75 |
| 01/26/2006 | US20060019294 Tyrosine kinase substrate (Tks) proteins |
| 01/26/2006 | US20060019240 Posh nucleic acids, polypeptides and related methods |
| 01/26/2006 | US20060018961 Compression formed preparation and method for manufacturing same |
| 01/26/2006 | US20060018959 Solid drug for oral use |
| 01/26/2006 | US20060018893 Method for determining modulation of P110delta activity |
| 01/26/2006 | US20060018884 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
| 01/26/2006 | CA2612303A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | CA2574381A1 Composition comprising protein material and non-oxidizable fatty acid entities |
| 01/26/2006 | CA2574366A1 Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities |
| 01/26/2006 | CA2574354A1 Imidazole and thiazole derivatives as antiviral agents |
| 01/26/2006 | CA2574232A1 Use of compounds containing thiol groups as an efflux pump inhibitor |
| 01/26/2006 | CA2572793A1 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
| 01/26/2006 | CA2570887A1 Tumor treatment |
| 01/26/2006 | CA2570602A1 Agents for regulating the activity of interferon-producing cells |
| 01/26/2006 | CA2570433A1 Medicaments for inhalation comprising pde iv inhibitors and enantiomerically pure glycopyrrolate salts |
| 01/25/2006 | EP1619498A2 Method of screening remedy for heart disease and medicinal composition for treating heart disease |
| 01/25/2006 | EP1619249A1 Induction of exon skipping in eukaryotic cells |